Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2022-09-27 Regulatory Filings
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release from Pherecydes Pharma announcing the management team's participation in several upcoming scientific and investor conferences, listing the names, dates, and locations of these events. It also mentions the date for the next financial publication (2022 half-year results). This type of announcement, detailing management activities, investor outreach, and future event schedules, is best classified as a general corporate update or investor relations communication. Since there is no specific category for 'Conference Participation Announcement,' and it is not a formal regulatory filing (like 10-K, ER, or IR), the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for non-standard corporate news releases, or potentially 'Investor Presentation' (IP) if the context implied a presentation was being given, but here it is just an announcement of attendance. Given the nature of announcing participation in investor events, it aligns closely with general investor communications. However, RNS is the designated fallback for miscellaneous announcements. Since it is not a formal report, dividend, or management change, RNS is the safest classification based on the provided definitions, although it is a very specific type of investor news release.
2022-09-27 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated September 27, 2022, announcing the participation of Pherecydes Pharma's management team in upcoming scientific conferences and investor events throughout September, October, and November 2022. It also mentions the upcoming release of 'Résultats semestriels 2022' (Half-year results) on October 27, 2022. Since the document itself is an announcement about future events and participation, and it is not the actual financial report (like an IR or 10-K), it fits best as a general announcement. Given the content focuses on investor engagement and upcoming financial reporting, it is a type of Investor Presentation/Update or a general Regulatory Filing. However, it is primarily an announcement detailing participation in investor/scientific meetings, which is often categorized under Investor Presentations (IP) or general Regulatory Filings (RNS). Since it is not a formal presentation deck (IP) but a news release detailing activities, and it is not a specific regulatory form, RNS (Regulatory Filings) is the most appropriate fallback for a general corporate announcement that doesn't fit the other specific categories like ER, DIV, or CAP. It is not a Report Publication Announcement (RPA) because it is announcing participation in events, not the publication of a specific report mentioned in the definitions (like 10-K or IR). Therefore, RNS is the best fit.
2022-09-27 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated September 22, 2022, announcing the successful completion of a capital increase totaling €3.1 million. The text details the purpose of the funds (clinical development, manufacturing), the terms of the financing (issuance of new shares, pricing, discount), shareholder subscription commitments, and resulting share capital structure changes. This content directly relates to fundraising, financing activities, and capital structure changes, which aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the AGM resolutions that authorized the capital increase, the primary focus is the execution and results of the financing itself, not the AGM materials or voting results.
2022-09-22 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 22, 2022, announcing the successful completion of a capital increase ('levée de fonds') totaling €3.1 million. It details the use of the raised funds, the characteristics of the offering (including placement global and PrimaryBid offer), the pricing, and the resulting shareholder structure changes. This content directly relates to the company's fundraising and capital structure activities. According to the definitions, 'Capital/Financing Update' (Code: CAP) is the appropriate classification for updates on company fundraising or financing activities.
2022-09-22 French
Inside Information / Other news releases
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the launch of a capital increase (issuance of new common shares) totaling approximately €3 million. Key phrases include 'launches a capital increase', 'Global Offering', 'Subscription commitments', and detailed terms of the financing operation. This clearly falls under the category of updates on company fundraising or capital structure changes. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification.
2022-09-21 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the launch of a fundraising effort ('levée de fonds') by Pherecydes Pharma, aiming to raise approximately 3 M€ through the issuance of new ordinary shares via a Global Offering and a PrimaryBid offering for retail investors. It details the use of proceeds (financing clinical development) and the structure of the capital increase (Offre Réservée, Placement Privé, Offre PrimaryBid). This content directly relates to company fundraising, financing activities, and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-09-21 French

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.